Putting Science to Work
Milestone

Milestones

  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2007
  • 2006
  • 2004
  • 2003
  • 2000
  • 1999
  • 1998
  • 1994

2016

  • Acquisition of Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expansion into Bioinformatics & NGS Services

  • Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC), our fourth dedicated R&D center.

  • Crossed an annual turnover of rupees 10,000 Millions .

2015

  • Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India.

  • Clinigene International was amalgamated with Syngene.

2014

  • Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D centre till 2020.

  • Acceptance of Syngene API manufacturing facility by the Department of Health & Human Services, US Food and Drug Administration.

  • Established a 75,000 sq. ft. Centre to provide stability and analytical services.

2013

  • Crossed an annual turnover of Rs 5,000 million.

  • Baxter International Inc. collaborated with Syngene to establish the ‘Baxter Global Research Center’, our third dedicated R&D centre.

  • Acceptance of Control Testing Laboratory by the Department of Health & Human Services, US Food and Drug Administration

2012

  • Abbott collaborated with Syngene to establish Abbott's first nutrition research & development center in India.

  • Received ANVISA Certification of clinical facilities.

  • Acquired 100% stake in Clinigene International Limited from Biocon.

2011

  • Endo Pharmaceuticals USA (NASDAQ: ENDP) signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer.

2010

  • Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, US Food and Drug Administration.

2009

  • Expansion of manufacturing services with a new cGMP plant

  •    

    Initiated operations in safety assessment, formulation development and biologics development services

2007

  •  

    Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Centre

  • Expansion of 115,000 sq ft of research laboratory as a part of our development program.

2006

  • Crossed an annual turnover of   1,000 million.

2004

  • Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.  

2003

  • Forayed into chemical development with a dedicated manufacturing facility.

2000

  • CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.

1999

  • First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.

1998

  • Granted 100% Export Oriented Unit (EOU) status by the Government of India

1994

  • Initiated operations as a CRO with services in chemistry and biology

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

FB Side
Inactive